A case of colon cancer combined with chronic renal dysfunction that responded to treatment with modified mFOLFOX6 plus bevacizumab therapy

Miyazaki Mieko, Nagafuchi Kazumitsu, Kosaka Kazuhide, Inoshita Shunichi, Sakurai Toshihiro, Tamura Masahito

doi:10.4009/jsdt.49.431

Bibliographic Information

Other Title

血液透析患者の大腸癌肝転移にmFOLFOX6+Bevacizumab療法が奏効した1例
症例報告血液透析患者の大腸癌肝転移にmFOLFOX6+Bevacizumab療法が奏効した1例
ショウレイホウコクケツエキトウセキカンジャノダイチョウガンカンテンイニ mFOLFOX6+Bevacizumab リョウホウガソウコウシタ 1レイ

Search this article

Description

A 73-year-old male with diabetic nephropathy underwent surgical resection for cancer of the sigmoid and rectum colon. Seven months after the surgery, an elevated serum carcinoembryonic antigen level and two liver metastases were detected after the patient underwent hemodialysis. Chemotherapy involving the modified FOLFOX6 (mFOLFOX6) regimen plus bevacizumab (BV) was initiated for the liver metastases. The dose of oxaliplatin was 65 mg/m², and that of bevacizumab was 3.5 mg/kg. Hemodialysis was started after the administration of oxaliplatin on day 1. Vomiting (grade 3) and hypertension (grade 3) were observed after five treatment cycles. However, no BV-specific adverse events, such as neutropenia, were observed during these five treatment cycles. We started the oral administration of UFT (tegafur/uracil) chemotherapy, as the patient rejected further mFOLFOX6 + BV therapy. A computed tomography scan obtained at 12 months after the initiation of chemotherapy showed that the liver metastases had disappeared. It is considered possible that mFOLFOX6 + BV therapy is safe and useful and does not cause severe side effects in hemodialysis patients, although there have been few reports about the use of chemotherapy in hemodialysis patients.

Journal

Nihon Toseki Igakkai Zasshi

Nihon Toseki Igakkai Zasshi 49 (6), 431-437, 2016

The Japanese Society for Dialysis Therapy

Keywords

Details 詳細情報について

Export

Report a problem